3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Lunai Bioworks received a Nasdaq determination that it no longer meets the $2,500,000 minimum stockholders' equity requirement, citing a stockholders' deficit of $(9,024,946). The company's board approved voluntary withdrawal of its common stock from Nasdaq and from registration under the Exchange Act, and it will not request a hearing. Trading on Nasdaq is expected to be suspended on October 30, 2026, and shareholders may have no over-the-counter quotation or trading market after that.
Stockholders' deficit of $(9,024,946) in the fiscal year ended June 30, 2026 10-K, versus the $2,500,000 minimum
Nasdaq trading expected to be suspended at the opening of business on October 30, 2026, unless a hearing is requested by October 28, 2026; the company does not intend to request one
Form 25 expected on or about November 2, 2026, with delisting effective on or about November 12, 2026
Chief Financial Officer Nathen Fuentes resigned effective October 22, 2026, with no successor appointed; the company does not intend to quote its stock over the counter
Atlantic American Corporation received a Nasdaq Staff Delisting Determination on October 16, 2026, because it had not filed its 2025 Form 10-K and two 2026 Forms 10-Q by the October 12, 2026 deadline. The company filed the 2025 10-K on October 16 and plans to request a Nasdaq Hearings Panel appeal by October 23, 2026, which would temporarily stay suspension of its stock.
Nasdaq Staff Determination received October 16, 2026 under Listing Rule 5250(c)(1)
2025 Form 10-K filed October 16, 2026; 10-Qs for quarters ended March 31 and June 30, 2026 remain unfiled
Hearing request due by October 23, 2026; hearings typically 30 to 45 days after request
Request automatically stays suspension for 15 days; no assurance of an extended stay
Nasdaq told ARC Group Acquisition I Corp that its warrants were out of compliance because their aggregate market value was below $1 million, and granted an extension to regain compliance by February 23, 2027. If the company does not meet the terms by that date, Nasdaq will notify it that its securities will be delisted, and the company may appeal to a Listing Qualifications Panel. The company says it expects to complete its previously announced business combination before that deadline.
Warrants' aggregate market value fell below the $1 million Nasdaq minimum under Listing Rule 5452(b)(C)
Company submitted its plan to regain compliance on October 12, 2026
Nasdaq granted an extension to regain compliance until February 23, 2027
Company expects to complete its previously announced business combination before February 23, 2027
The FDA lifted the clinical hold on the Investigational New Drug application for Aardvark's ARD-101 for hyperphagia in Prader-Willi Syndrome, and Aardvark said clinical development may resume. Resumption still depends on further engagement with the FDA on the Phase 3 trial design, and the company describes the Phase 3 HERO trial and its open-label extension as terminated.
FDA lifted the clinical hold on the ARD-101 IND, following a hold placed in May 2026 on the HERO and OLE trials
Dosing in the HERO trial was voluntarily paused on February 27, 2026 after reversible ECG changes in a separate healthy-volunteer study
A recent ECG study observed no cardiac events at ARD-101 doses of 200 mg and 400 mg twice daily
Aardvark will host a webcast on October 23, 2026 at 8:00 a.m. ET to review exploratory Phase 3 HERO and OLE data
Nasdaq notified Globa Terra Acquisition Corp on October 16, 2026, that it has not completed a business combination within the required timeframe, and has begun procedures to delist its securities. The company intends to request a hearing before a Nasdaq Hearing Panel, which would keep its shares listed while the appeal is pending, but there is no assurance the appeal will succeed.
Nasdaq Staff Determination received October 16, 2026, citing failure to complete a business combination within the required timeframe under IM-5101-2(b)
Hearing request deadline is 4:00 p.m. Eastern Time on October 23, 2026
If no hearing is requested, trading suspension begins at the opening of business on October 27, 2026
The company is seeking a shareholder extension of its deadline to July 9, 2027
SenesTech received a Nasdaq letter on October 20, 2026, saying its stock has closed below $1.00 for 30 consecutive business days, so it no longer meets Nasdaq's minimum bid price requirement. The company has until April 19, 2027 to regain compliance, and the notice has no immediate effect on its listing, but the company says it cannot assure it will regain compliance. In the same release, the company reported preliminary third-quarter revenue of about $1.1 million, the highest in its history.
Nasdaq notice received October 20, 2026; stock closed below $1.00 for 30 consecutive business days
Compliance period ends April 19, 2027; regaining compliance requires a closing bid of $1.00 or more for at least 10 consecutive business days
Preliminary Q3 revenue of about $1.1 million, up 40% from Q2 and 55% from Q3 2025
Long-term holder Glenbrook Capital Management reports a 38% ownership position and has offered to work with the board and management
Arbutus Biopharma announced that the U.S. Food and Drug Administration removed the clinical hold on the Investigational New Drug application for AB-101, its oral PD-L1 inhibitor for chronic hepatitis B. The company may now engage in additional clinical development of AB-101 in the United States and says it is evaluating next steps.
FDA removed the clinical hold on the IND application for AB-101, announced October 22, 2026
AB-101 completed a Phase 1a/1b trial, which the company says was generally well-tolerated
Trial data showed high receptor occupancy in seven chronic HBV patients and hepatitis B surface antigen decline in two patients at the 30mg dose
Biohaven said the FDA accepted its new drug application resubmission for Vyglxia (troriluzole) in spinocerebellar ataxia (SCA) and considers it a complete response to the November 4, 2025 action letter. The FDA set a user fee goal date in the first quarter of 2027 and plans an advisory committee meeting, with the date to be announced later, so approval is not assured.
FDA accepted the NDA resubmission for Vyglxia (troriluzole) in SCA, which includes new supportive analyses.
FDA considers the resubmission a complete response to the November 4, 2025 action letter.
User fee goal date set for the first quarter of 2027; advisory committee meeting date to be announced in the near term.
Quest Diagnostics said on October 21, 2026 it learned of unauthorized access to its Quanum LSM system, which clients use to place test orders and look up results. The company believes an unauthorized party accessed certain patient records, and the full scope is still under investigation. The company said the incident has not materially disrupted its business operations or its ability to serve patients.
Unauthorized access to Quanum LSM system discovered October 21, 2026
Company believes certain patient records were accessed; full scope under investigation
Federal law enforcement notified and external cybersecurity experts engaged
Company states business operations and patient service not materially disrupted
Cognition Therapeutics said the FDA has aligned with it on key elements of a Phase 3 study of zervimesine in dementia with Lewy bodies, including patient selection, dose, duration and endpoints. The company is now completing a protocol for the planned registrational study, which the filing describes as covering a disease with no approved treatments. The filing contains no financial figures, so the update's effect on shareholders depends on the trial's future results and regulatory path.
Planned study will randomize participants with mild-to-moderate DLB to 100 mg once-daily oral zervimesine or placebo for nine months
Primary endpoint is the NPI-2 neuropsychiatric inventory measuring hallucinations and delusions
Key secondary endpoint is the ADCS-ADL scale, which evaluates effects on daily function
The announcement was made October 22, 2026, in a press release filed as Exhibit 99.1
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.